First ‘targeted’ treatment for small cell lung cancer shows promise

Dr Pietanza talks to ecancertv at ECC 2015 about a phase I study with the investigational agent rovalpituzumab tesirine (Rova-T) in patients with small cell lung cancer (SCLC).

During the interview she explains how Rova-T may offer new hope for patients with SCLC in whom treatment options can be limited due to diagnosis at a late stage when the disease has already metastasized.